We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Prediction of the Effectiveness of Hypofractionated Radiation Therapy in Early Stage Lung Cancer by Bio-imaging and Biomarkers (PEARL-2)

This study has been terminated.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01138748
First Posted: June 7, 2010
Last Update Posted: February 4, 2013
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Nationaal Kankerplan
Information provided by (Responsible Party):
University Hospital, Ghent
June 4, 2010
June 7, 2010
February 4, 2013
November 2010
October 2012   (Final data collection date for primary outcome measure)
development and validation of a multi-variate predictive model [ Time Frame: from 2 to 5 years ]
To develop and validate a multi-variate predictive model based on bio-imaging and biomarkers for progression)free survival from 2 to 5 years.
Progression free survival (PFS) [ Time Frame: at 2 years ]

RX at screening, EOT, 3M,6M ,9M ,12M ,18M, 24M.

After completion of the study treatment, patients are followed periodically for 5 years

Complete list of historical versions of study NCT01138748 on ClinicalTrials.gov Archive Site
  • the clinical response and complication rate [ Time Frame: from 2 to 5 years ]
  • local, regional or distant failure [ Time Frame: from 2 to 5 years ]
  • progression free survival [ Time Frame: from 2 to 5 years ]
  • disease specific overall survival [ Time Frame: from 2 to 5 years ]
  • the completion rate [ Time Frame: until 2 years ]
    RX at screening, EOT, 3M,6M ,9M ,12M ,18M, 24M. FACT-L questionnaire at screening, EOT and every visit until 24M
  • quality of life [ Time Frame: until 2 years ]
    RX at screening, EOT, 3M,6M ,9M ,12M ,18M, 24M. FACT-L questionnaire at screening, EOT and every visit until 24M
  • local, regional or distant failure [ Time Frame: until 2 years ]
    RX at screening, EOT, 3M,6M ,9M ,12M ,18M, 24M. FACT-L questionnaire at screening, EOT and every visit until 24M
  • disease free survival [ Time Frame: at 2 years ]
    RX at screening, EOT, 3M,6M ,9M ,12M ,18M, 24M. FACT-L questionnaire at screening, EOT and every visit until 24M
  • disease specific overall survival [ Time Frame: at 2 years ]
    RX at screening, EOT, 3M,6M ,9M ,12M ,18M, 24M. FACT-L questionnaire at screening, EOT and every visit until 24M
Not Provided
Not Provided
 
Prediction of the Effectiveness of Hypofractionated Radiation Therapy in Early Stage Lung Cancer by Bio-imaging and Biomarkers
Prediction of the Effectiveness of Hypofractionated Radiation Therapy in Early Stage Lung Cancer by Bio-imaging and Biomarkers

Surgical resection with mediastinal lymph node sampling is currently the therapy of choice for early stage (I-II) non-small cell lung cancer (NSCLC). Selected patients unwilling or unable to tolerate surgery are referred for so-called 'curative' high dose radiotherapy. This has shown to result in a long term local disease control rate and a high cancer specific survival.

The current trial addresses the issue if progression free survival (PFS) in patients treated with radiotherapy can be predicted by a multi-variate model derived from a composite of bio-imaging and biomarkers

Not Provided
Interventional
Phase 2
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Inoperable Early Stage Non-small Cell Lung Cancer
Radiation: hypofractionated radiation therapy
hypofractionated radiation therapy
Experimental: Radiation therapy
Intervention: Radiation: hypofractionated radiation therapy
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
5
October 2012
October 2012   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Proof of cT1a/b - 2a/b N0M0 NSCLC
  • Informed Consent signed
  • Resectable tumour
  • > 18 years old
  • men and women
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Belgium
 
 
NCT01138748
2010/205
LONG 10-01 ( Other Identifier: University Hospital Ghent )
No
Not Provided
Not Provided
University Hospital, Ghent
University Hospital, Ghent
Nationaal Kankerplan
Principal Investigator: Jan Van Meerbeeck, MD,PhD University Hospital, Ghent
University Hospital, Ghent
February 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP